Hydrodissection With Neuroprolotherapy Versus Open Release for Carpal Tunnel Syndrome

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-70
SponsorUniversidade Federal de Pernambuco

About this trial

This study is a randomized controlled, parallel-group, non-inferiority trial designed to compare ultrasound-guided hydrodissection combined with neuroprolotherapy versus open carpal tunnel release in patients with carpal tunnel syndrome. Participants will be randomly allocated in a 1:1 ratio using a computer-generated sequence, with allocation concealment ensured by sequentially numbered, sealed, opaque envelopes. Outcome assessment and statistical analysis will be performed by blinded evaluators.

The experimental group will undergo a single session of ultrasound-guided hydrodissection with perineural injection of a solution composed of zero point nine percent sodium chloride and five percent dextrose, combined with local anesthetic and betamethasone, aiming to promote mechanical release of the median nerve and modulation of the inflammatory process. The control group will undergo standard open carpal tunnel release through surgical division of the transverse carpal ligament under sterile conditions.

Participants will be assessed at baseline, and at 1, 3, and 6 months after intervention. The primary outcome is the change in the Boston Carpal Tunnel Questionnaire score at 3 months. A non-inferiority margin of 0.5 points will be adopted. Secondary outcomes include pain intensity measured by visual analog scale, grip strength, pinch strength, median nerve cross-sectional area assessed by ultrasound, time to return to work, and procedure-related complications.

Statistical analysis will follow the intention-to-treat principle, with complementary per-protocol analysis. Between-group comparisons will be conducted using analysis of covariance adjusted for baseline values, and repeated measures will be analyzed using mixed-effects models. The hypothesis is that the minimally invasive intervention is non-inferior to surgical decompression, with potential advantages in recovery and morbidity.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Adults aged 18 years or olde

Clinical diagnosis of carpal tunnel syndrome

Presence of symptoms for at least 3 months

Failure of conservative treatment, including splinting, medication, or physical therapy

Disqualifiers

Previous carpal tunnel surgery in the affected limb

Severe thenar muscle atrophy

Cervical radiculopathy or proximal nerve compression

Pregnancy

Trial design

Design model

Parallel

Treatments tested in this trial

  • Ultrasound-guided Hydrodissection of the Median Nerve

    Procedure/Surgery

    Ultrasound-guided perineural injection using saline and dextrose solution combined with local anesthetic and betamethasone for mechanical release of the median nerve.

  • Open Carpal Tunnel Release

    Procedure/Surgery

    Participants will undergo open carpal tunnel release performed under sterile conditions in an operating room, using local or regional anesthesia, through a longitudinal palmar incision with division of the transverse carpal ligament to decompress the median nerve, followed by hemostasis, layered closure, and compressive dressing.

Treatment groups

72 Participants
are divided into 2 treatment groups
Group A: Hydrodissection + NeuroprolotherapyExperimental treatment 1 intervention
Group B: Open Carpal Tunnel ReleaseActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Change in Boston Carpal Tunnel Questionnaire score

Change from baseline in the Boston Carpal Tunnel Questionnaire total score at 3 months. The primary analysis will assess the between-group difference using a non-inferiority framework with a predefined margin of 0.5 points. Lower scores indicate better outcomes.

Time frame
Baseline to 3 months

Secondary outcomes

1

Change in pain intensity (Visual Analog Scale)

Pain intensity measured using a visual analog scale ranging from 0 to 10, with higher scores indicating greater pain. Clinically significant improvement defined as a reduction of at least 2 points or 30 percent from baseline.

Time frame
Baseline, 1 month, 3 months, and 6 months
2

Change in grip strength

Grip strength measured using hand dynamometry. Improvement defined as an increase of at least 20 percent from baseline.

Time frame
Baseline, 1 month, 3 months, and 6 months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: